Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9912 |
Trastuzumab
|
EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
Trastuzumab 是人源化单克隆抗体,以高亲和力与HER2选择性结合,可用于 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌的研究。 | |||
T36646 |
Trastuzumab deruxtecan
DS-8201a,VRN-101099,DS 8201,T-DXd |
Others | Others |
Trastuzumab deruxtecan (T-DXd) 是一种具有抗癌抗肿瘤活性的抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 对 HER2 阳性乳腺癌和胃癌有改善作用。 | |||
T77440 |
Codrituzumab
RG-7686,RO5137382,GC33 |
||
Codrituzumab (GC3)是一种人源化针对 glypican-3 肝癌蛋白的抗体,可与索拉非尼联合使用来研究不可治愈的晚期肝细胞癌 (HCC) 。 | |||
T36647 | Trastuzumab emtansine | Others | Others |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that combines the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of DM1, a microtubule-inhibitory derivative of maytansine. This compound is utilized in the investigation of advanced breast cancer[1][2]. | |||
T9996 |
NCT-58
NCT58 |
HSP | Cytoskeletal Signaling; Metabolism |
NCT-58是一种有效的C 端HSP90抑制剂。NCT-58不会引起热休克反应(HSR)。NCT-58通过同时下调HER 家族成员以及抑制Akt 磷酸化来激发抗肿瘤活性。NCT-58杀死对曲妥珠单抗耐药的乳腺癌干细胞样细胞。NCT-58诱导HER2阳性乳腺癌细胞凋亡。 |